GSK (GSK) said Wednesday that risvutatug rezetecan has received the orphan drug designation from the US Food and Drug Administration to treat small-cell lung cancer.
The status was granted based on preliminary data demonstrating "durable responses" in patients with extensive-stage cancer in a phase I clinical trial, the company said.
Risvutatug rezetecan has now received five regulatory designations, according to GSK.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments